Longeveron Inc. (LGVN)
NASDAQ: LGVN · Real-Time Price · USD
0.716
-0.014 (-1.85%)
At close: Jun 26, 2026, 4:00 PM EDT
0.710
-0.006 (-0.78%)
After-hours: Jun 26, 2026, 7:24 PM EDT
Company Description
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States.
Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer’s disease, as well as in phase 2b clinical trial to treat aging frailty.
The company was incorporated in 2014 and is headquartered in Miami, Florida.
Longeveron Inc.
| Country | United States |
| Founded | 2014 |
| IPO Date | Feb 12, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 38 |
| CEO | Stephen Willard |
Contact Details
Address: Life Science & Technology Park, Suite 520 Miami, Florida 33136 United States | |
| Phone | 844 470 2550 |
| Website | longeveron.com |
Stock Details
| Ticker Symbol | LGVN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0001721484 |
| CUSIP Number | 54303L104 |
| ISIN Number | US54303L2034 |
| Employer ID | 47-2174146 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Stephen H. Willard Esq. | Chief Executive Officer |
| Dr. Joshua Michael Hare FACC, M.D. | Co-Founder, Chief Science Officer and Executive Chairman |
| Lisa A. Locklear M.B.A. | Chief Financial Officer, Executive Vice President and Treasurer |
| Paul T. Lehr J.D. | General Counsel and Secretary |
| Devin Blass | Chief Technology Officer and Senior Vice President of Chemistry, Manufacturing and Controls |
| Dr. Nataliya Agafonova M.D. | Chief Medical Officer |
| Lisa McClain-Moss | Vice President of Manufacturing |
| Brian G Rash Ph.D. | Vice President of Research and Discovery |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 5, 2026 | 8-K | Current Report |
| May 20, 2026 | ARS | Filing |
| May 20, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 20, 2026 | DEF 14A | Other definitive proxy statements |
| May 15, 2026 | SCHEDULE 13G | Filing |
| May 13, 2026 | 8-K | Current Report |
| May 13, 2026 | 10-Q | Quarterly Report |
| May 8, 2026 | 8-K | Current Report |
| May 5, 2026 | PRE 14A | Other preliminary proxy statements |
| Apr 17, 2026 | EFFECT | Notice of Effectiveness |